This “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.
"Gout - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Geography Covered
- Global coverage
Gout Understanding
Gout: Overview
Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.
"Gout - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.
Gout Emerging Drugs Chapters
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
- SEL 212: Selecta Biosciences
- URC 102: JW Pharmaceuticals
Gout: Therapeutic Assessment
This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Gout
There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.
The report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Gout Report Insights
- Gout Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Gout Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gout drugs?
- How many Gout drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gout and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Selecta Biosciences
- JW Pharmaceuticals
- Astrazeneca
- Revive Therapeutics
- Fuji Yakuhin Co., Ltd.
- Arthrosi Therapeutics
Key Products
- SEL 212
- URC 102
- Verinurad
- AR882
- FYU-981
Table of Contents
IntroductionExecutive Summary
Gout: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Gout - Analytical Perspective
In-depth Commercial Assessment
- Gout companies' collaborations, Licensing, Acquisition - Deal Value Trends
Gout Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
SEL 212: Selecta Biosciences
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
URC-102: JW Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Gout Key Companies
Gout Key Products
Gout - Unmet Needs
Gout - Market Drivers and Barriers
Gout - Future Perspectives and Conclusion
Gout Analyst Views
Gout Key Companies
AppendixList of Tables
Table 1 Total Products for Gout
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Gout
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Selecta Biosciences
- JW Pharmaceuticals
- Astrazeneca
- Revive Therapeutics
- Fuji Yakuhin Co., Ltd.
- Arthrosi Therapeutics
